Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Cancer Cell

Volumn 11, Issue 3, 2007, Pages 217-227

  Yun, Cai Hong ^a,b   Boggon, Titus J ^a,b   Li, Yiqun ^b   Woo, Michele S ^b   Greulich, Heidi ^b,c   Meyerson, Matthew ^a,b,c   Eck, Michael J ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; AFN 941; ARGININE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; GLYCINE; LEUCINE; SERINE; STAUROSPORINE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING; DRUG MECHANISM; DRUG SENSITIVITY; DRUG STRUCTURE; ENZYME ACTIVATION; GENE INTERACTION; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG CANCER; MEASUREMENT; MUTANT; PRIORITY JOURNAL; WILD TYPE;

EID: 33847406095     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2006.12.017     Document Type: Article

References (52)

1. Amann J., Kalyankrishna S., Massion P.P., Ohm J.E., Girard L., Shigematsu H., Peyton M., Juroske D., Huang Y., Stuart S.J., et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 65 (2005) 226-235
2. Arao T., Fukumoto H., Takeda M., Tamura T., Saijo N., and Nishio K. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res. 64 (2004) 9101-9104
3. Auffinger P., Hays F.A., Westhof E., and Ho P.S. Halogen bonds in biological molecules. Proc. Natl. Acad. Sci. USA 101 (2004) 16789-16794
4. Barker S.C., Kassel D.B., Weigl D., Huang X., Luther M.A., and Knight W.B. Characterization of pp60c-src tyrosine kinase activities using a continuous assay: Autoactivation of the enzyme is an intermolecular autophosphorylation process. Biochemistry 34 (1995) 14843-14851
5. Barker A.J., Gibson K.H., Grundy W., Godfrey A.A., Barlow J.J., Healy M.P., Woodburn J.R., Ashton S.E., Curry B.J., Scarlett L., et al. Studies leading to the identification of ZD1839 (IRESSA): An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett. 11 (2001) 1911-1914
6. Boggon T.J., Li Y., Manley P.W., and Eck M.J. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 106 (2005) 996-1002
7. Brignola P.S., Lackey K., Kadwell S.H., Hoffman C., Horne E., Carter H.L., Stuart J.D., Blackburn K., Moyer M.B., Alligood K.J., et al. Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors. J. Biol. Chem. 277 (2002) 1576-1585
8. Brünger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S., et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54 (1998) 905-921
9. Capdeville R., Silberman S., and Dimitrijevic S. Imatinib: The first 3 years. Eur. J. Cancer 38 Suppl 5 (2002) S77-S82
10. Carey K.D., Garton A.J., Romero M.S., Kahler J., Thomson S., Ross S., Park F., Haley J.D., Gibson N., and Sliwkowski M.X. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 66 (2006) 8163-8171
11. Chan S.K., Gullick W.J., and Hill M.E. Mutations of the epidermal growth factor receptor in non-small cell lung cancer-Search and destroy. Eur. J. Cancer 42 (2006) 17-23
12. De Bondt H.L., Rosenblatt J., Jancarik J., Jones H.D., Morgan D.O., and Kim S.H. Crystal structure of cyclin-dependent kinase 2. Nature 363 (1993) 595-602
13. Ekstrand A.J., Sugawa N., James C.D., and Collins V.P. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. USA 89 (1992) 4309-4313
14. Emsley P., and Cowtan K. Coot: Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60 (2004) 2126-2132
15. Engelman J.A., Janne P.A., Mermel C., Pearlberg J., Mukohara T., Fleet C., Cichowski K., Johnson B.E., and Cantley L.C. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl. Acad. Sci. USA 102 (2005) 3788-3793
16. Fry D.W., Bridges A.J., Denny W.A., Doherty A., Greis K.D., Hicks J.L., Hook K.E., Keller P.R., Leopold W.R., Loo J.A., et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc. Natl. Acad. Sci. USA 95 (1998) 12022-12027
17. Gazdar A.F., Shigematsu H., Herz J., and Minna J.D. Mutations and addiction to EGFR: The Achilles 'heal' of lung cancers?. Trends Mol. Med. 10 (2004) 481-486
18. Greulich H., Chen T.H., Feng W., Janne P.A., Alvarez J.V., Zappaterra M., Bulmer S.E., Frank D.A., Hahn W.C., Sellers W.R., and Meyerson M. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2 (2005) e313 10.1371/journal.pmed.0020313
19. Hynes N.E., and Lane H.A. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 5 (2005) 341-354
20. Jiang J., Greulich H., Janne P.A., Sellers W.R., Meyerson M., and Griffin J.D. Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res. 65 (2005) 8968-8974
21. Johnson B.E., and Janne P.A. Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res. 65 (2005) 7525-7529
22. Jones T.A., Zou J.Y., Cowan S.W., and Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47 (1991) 110-119
23. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., and Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352 (2005) 786-792
24. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., Harris P.L., Driscoll D.R., Fidias P., Lynch T.J., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA 102 (2005) 7665-7670
25. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350 (2004) 2129-2139
26. Mukohara T., Engelman J.A., Hanna N.H., Yeap B.Y., Kobayashi S., Lindeman N., Halmos B., Pearlberg J., Tsuchihashi Z., Cantley L.C., et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J. Natl. Cancer Inst. 97 (2005) 1185-1194
27. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53 (1997) 240-255
28. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. In: Carter Jr. C.W., and Sweet R.M. (Eds). Methods in Enzymology, Volume 276: Macromolecular Crystallography, Part A (1997), Academic Press, New York 307-326
29. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304 (2004) 1497-1500
30. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101 (2004) 13306-13311
31. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., and Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS. Med. 2 (2005) e73
32. Perrakis A., Morris R., and Lamzin V.S. Automated protein model building combined with iterative structure refinement. Nat. Struct. Biol. 6 (1999) 458-463
33. Pollack V.A., Savage D.M., Baker D.A., Tsaparikos K.E., Sloan D.E., Moyer J.D., Barbacci E.G., Pustilnik L.R., Smolarek T.A., Davis J.A., et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther. 291 (1999) 739-748
34. Read R.J. Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr. D Biol. Crystallogr. 57 (2001) 1373-1382
35. Rusnak D.W., Lackey K., Affleck K., Wood E.R., Alligood K.J., Rhodes N., Keith B.R., Murray D.M., Knight W.B., Mullin R.J., and Gilmer T.M. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol. Cancer Ther. 1 (2001) 85-94
36. Schlessinger J. Common and distinct elements in cellular signaling via EGF and FGF receptors. Science 306 (2004) 1506-1507
37. Schuttelkopf A.W., and van Aalten D.M. PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 60 (2004) 1355-1363
38. Shigematsu H., and Gazdar A.F. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int. J. Cancer 118 (2006) 257-262
39. Sicheri F., Moarefi I., and Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature 385 (1997) 602-609
40. Sordella R., Bell D.W., Haber D.A., and Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305 (2004) 1163-1167
41. Stamos J., Sliwkowski M.X., and Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277 (2002) 46265-46272
42. Tice D.A., Biscardi J.S., Nickles A.L., and Parsons S.J. Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc. Natl. Acad. Sci. USA 96 (1999) 1415-1420
43. Traxler P., Allegrini P.R., Brandt R., Brueggen J., Cozens R., Fabbro D., Grosios K., Lane H.A., McSheehy P., Mestan J., et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 64 (2004) 4931-4941
44. Tsou H.R., Overbeek-Klumpers E.G., Hallett W.A., Reich M.F., Floyd M.B., Johnson B.D., Michalak R.S., Nilakantan R., Discafani C., Golas J., et al. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J. Med. Chem. 48 (2005) 1107-1131
45. Wakeling A.E., Guy S.P., Woodburn J.R., Ashton S.E., Curry B.J., Barker A.J., and Gibson K.H. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62 (2002) 5749-5754
46. Williams J.C., Weijland A., Gonfloni S., Thompson A., Courtneidge S.A., Superti-Furga G., and Wierenga R.K. The 2.35 A crystal structure of the inactivated form of chicken Src: A dynamic molecule with multiple regulatory interactions. J. Mol. Biol. 274 (1997) 757-775
47. Wood E.R., Truesdale A.T., McDonald O.B., Yuan D., Hassell A., Dickerson S.H., Ellis B., Pennisi C., Horne E., Lackey K., et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64 (2004) 6652-6659
48. Xu W., Harrison S.C., and Eck M.J. Three-dimensional structure of the tyrosine kinase c-Src. Nature 385 (1997) 595-602
49. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol. 2 (2001) 127-137
50. Yuza Y., Glatt K.A., Jiang J., Greulich H., Minami Y., Woo M.S., Shimamura T., Shapiro G., Lee J.C., Ji H., et al. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biol. Ther. (2007) in press
51. Zhang X., Gureasko J., Shen K., Cole P.A., and Kuriyan J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125 (2006) 1137-1149
52. Zhu X., Kim J.L., Newcomb J.R., Rose P.E., Stover D.R., Toledo L.M., Zhao H., and Morgenstern K.A. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure 7 (1999) 651-661